Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 127

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 127
---
 may own or co-own intellectual property covering our product candidates or research programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize 
 such intellectual property or such product candidates or research programs;                                                                                                                                                       |

| • | we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us; |

| • | collaborators may control certain interactions with regulatory authorities, which may impact our ability to obtain and maintain regulatory approval of our product candidates; |

| • | disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or research programs or that result in costly litigation or 
 arbitration that diverts management attention and resources;                                                                                                                                                                        |

67 Table of Contents

| • | collaborators may decide to not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, 
 changes in the collaborator’s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;                                                          |

| • | collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a 
 product candidate for clinical testing;                                                                                                                                                                                           |

| • | collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or research programs if the collaborators believe that competitive products are 
 more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;                                                                                                     |

| • | collaborators may restrict us from researching, developing or commercializing certain products or technologies without their involvement; |

| • | collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates; |

| • | we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control; |

| • | collaborators may grant sublicenses to our technology or product candidates or undergo a change of control and the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest; |

| • | collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, know